Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Short Communication Volume 5 Issue 11

Fluvoxamine - A Potential New Drug to Treat Covid-19 in Early Stage

Tapan K Chaudhuri* and Richard Hoffler

Hampton, Virginia and San Antonio, Texas, USA

*Corresponding Author: Tapan K Chaudhuri, Professor, Hampton, Virginia, USA.

Received: August 27, 2021; Published: October 8, 2021


Fluvoxamine [1], a commonly prescribed drug to treat depression and Obsessive Compulsive Disorder (OCD) has been found to be effective in COVID-19 in early stage - within 7 days of developing symptoms.

Fluvoxamine tablet 100 mg BID for 10 days in early stage of the COVID-19 has been found to reduce the need of extended emergency room observation, hospitalization, ICU admission and ventilator.

Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) and a Sigma-1 receptor (S1R) agonist, an essential inhibitor of cytokine production.



Citation: Tapan K Chaudhuri and Richard Hoffler. “Fluvoxamine - A Potential New Drug to Treat Covid-19 in Early Stage". Acta Scientific Pharmaceutical Sciences 5.11 (2020):.


Acceptance rate32%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US